- Premium Stock Alerts
- Posts
- Wall Street Wake-Up Call: Stock Futures & Pre-Market Buzz
Wall Street Wake-Up Call: Stock Futures & Pre-Market Buzz
Don’t want emails from us anymore? Click here to unsubscribe
Hello Part-time Trader…👋
Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:
Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.
Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.
Top Pre-Market Movers: Identify early winners poised for a strong market opening.
Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.
FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.
Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.
Sponsored
Bank of America Analysts Say this AI Company Could Grow 400% in the Next 3 Years
Some analysts say this company's 900% growth in the last year is a "one-and-done" pop, but Bank of America analysts disagree. In fact, they say it could go 4x higher in the next 3 years.
Click Here for the Stock Bank of America Says Could Quintuple Revenues 4x Over the Next 3 Years!
Happening Today
✓ 10:00 AM ET – CB Employment Trends Index (Apr)
✓ 11:30 AM ET – 3-Month Bill Auction
✓ 11:30 AM ET – 6-Month Bill Auction
✓ 12:50 PM ET – FOMC Member Barkin Speaks
✓ 01:00 PM ET – FOMC Member Williams Speaks
✓ 02:00 PM ET – Loan Officer Survey
PREMARKET SNAPSHOT 📈
Stock futures point to a positive open today, with NASDAQ 100 leading the gains at over 1.2%.
S&P500$5127.79 ⬆️ 1.25% | Dow$38675.68 ⬆️ 1.17% | NASDAQ$17890.795 ⬆️ 1.99% |
SECTOR SNAPSHOT ✨
Markets are mixed today with some sectors gaining and others losing ground. Information Technology leads the pack today, surging 3.01%.
NAME | PRICE | %CHANGE |
---|---|---|
Consumer Discretionary | 1,453.33 | +0.71% 🟢 |
Consumer Staples | 809.66 | +0.33% 🟢 |
Energy | 706.80 | -0.05% 🔴 |
Financials | 674.59 | +0.31% 🟢 |
Health Care | 1,640.42 | +0.23% 🟢 |
Industrials | 1,038.97 | +0.70% 🟢 |
Materials | 563.67 | +1.00% 🟢 |
Real Estate | 232.06 | +0.82% 🟢 |
Information Technology | 3,734.81 | +3.01% 🟢 |
Communication Services | 286.53 | +1.02% 🟢 |
Utilities | 347.36 | +0.86% 🟢 |
Sponsored
10 Best Stocks to Own in 2024
Enter your email address below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. You will also receive our free daily email newsletter with the latest buy and sell recommendations from Wall Street's top analysts.
Get the full list with our detailed analysis in our new report...
Unusual Volume
📈 Safe & Green Holdings Corp (SGBX) jumped 89.08% to $5.54 on a whopping 91.9 million shares traded after announcing that its subsidiary, SG Echo, is preparing to deliver its inaugural sustainable modular unit to a prominent quick-service restaurant customer in the Pacific Northwest.
📈 Investors went wild, sending Vaxxinity Inc (VAXX) stock soaring 35.41% to $0.14 on a massive volume of 56.35 million shares.
📈 Abnormal activity shook Bruush Oral Care Inc. (BRSH), pushing it up 14.12% to $0.07 on a whopping 51.07 million shares traded.
📈 Gerdau S.A. ADR (GGB) stock recently closed 5.26% upper at $3.80 on substantial volume of 36.45 million shares after reporting Q1 2024 financial results.
📈 Gamestop Corporation (GME) increase by 29.08% in a single trading session, with abnormally high trading volume of 35.83 million shares.
Sponsored
How to collect FAT dividend checks in the AI boom
Investing legend Tim Melvin reveals the #1 dividend stock for the AI Boom.
This stock is paying an ultra-fat dividend up to 12%!
Because according to the New York Times, "AI could soon need as much electricity as an entire COUNTRY." And this stock is perfectly positioned to get rich in an energy starved economy.
But you MUST buy before May 9th.
Click HERE to claim your FREE report.
Premarket Movers
XBP Europe Holdings, Inc. (XBP) experiences a substantial 68.86% surge in pre-market trading after announcing that the Company has been selected by His Majesty’s Passport Office as its technology and services partner on a nationwide project, which aims to make documents dating back to 1837 digitally available to the General Register Office.
Strong Global Entertainment, Inc. (SGE) sees a significant 57.00% increase, reaching a pre-market price of $1.77. FG Acquisition Corp. and Strong Global Entertainment, Inc. (SGE) are pleased to announce the proposed acquisition of Strong/MDI Screen Systems, Inc. by FGAC, pursuant to an acquisition agreement dated May 3, 2024 between FGAC, Strong Global, MDI, FGAC Investors LLC and CG Investments VII Inc.
Beneficient (BENF) demonstrates a noteworthy 17.30% surge, with a pre-market price of $9.00 after announcing that it has received notice from The Nasdaq Stock Market LLC that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
Pre Market Gainers | Pre Market Change | Pre Market Volume |
---|---|---|
FFIE | +4.40% | 4.93M |
XBP | +68.86% | 2.82M |
SGE | +57.00% | 1.86M |
OMH | +16.83% | 1.52M |
BENF | +19.50% | 838.46K |
NUVO | +12.25% | 483.37K |
MARA | +6.28% | 375.27K |
CRVS | +17.71% | 259.60K |
SBFM | +13.69% | 237.34K |
CLSK | +4.77% | 229.70K |
Sponsored
Revolutionary Autoimmune Care: Invest in Single-Day CAR-T Therapy
Embark on an investment journey, this Company is at the forefront of autoimmune disease therapy. Our trailblazing approach not only aims to significantly improve patient outcomes but also opens a lucrative market for discerning investors.
Join us in propelling healthcare innovation forward, and be part of a legacy in the making. Invest in a healthier future today. Read more about this exciting investment opportunity…
Click here to learn more.
Important FDA
Recently Announced
Day One Biopharmaceuticals, Inc. (DAWN) is celebrating FDA approval of their drug Tovorafenib, now marketed as OJEMDA. This medication offers new hope for children battling a specific type of brain tumor: relapsed or progressive pediatric low-grade glioma.
X4 Pharmaceuticals, Inc. (XFOR) can also boast an FDA thumbs-up for their drug Mavorixafor, now known as XOLREMDI. This medication addresses WHIM syndrome, a rare and challenging condition affecting those twelve and older.
Finally, Neurocrine Biosciences Inc (NBIX) has expanded the reach of their existing medication Ingrezza. The FDA recently approved a new sprinkle formulation, providing a more convenient way for adults with tardive dyskinesia and chorea associated with Huntington's disease to take their medication.
Upcoming Announcements
The coming days are packed with important FDA decisions on new drugs and vaccines. On May 9th, Pfizer (PFE) will learn the fate of their application for full approval of Tivdak (sBLA) for a specific use in recurrent or metastatic cervical cancer. Currently, Tivdak only has accelerated approval.
Next, on May 12th, the FDA will announce its verdict on Moderna, Inc's (MRNA) BLA for mRNA-1345, a vaccine targeting RSV. This vaccine has the potential to be a major breakthrough in public health.
Finally, on May 13th, Dynavax Technologies Corp (DVAX) will be looking for positive news from the FDA regarding their Biologics License Application (BLA) for HEPLISAV-B, a hepatitis B vaccine. The application focuses on expanding the vaccine's use in adults undergoing hemodialysis, a population particularly susceptible to the disease.
🎁 Looking for More? Check out these complementary newsletters for diverse perspectives:
|
Happy investing,
Maeve Grace
Editor In Chief
Premium Trade Alerts
Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.
Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.
Reply